Moderna will not be developing a vaccine to protect against bird flu — at least on the federal government’s dime. The U.S.

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...

Immunologists from the Institute have been the first to uncover a role for a family of RNA binding proteins in the function ...

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

HHS has notified Moderna that it is canceling a nearly $600 million contract for vaccines for flu strains that could trigger ...

The finding clarifies an important aspect of cell biology, and may have clinical implications, since this messenger RNA modification, known as m6A, is the target of an emerging class of cancer ...

With the continued use of COVID-19 vaccines worldwide, there’s a massive amount of data that shows mRNA shots are safe.